Article
Quinolone can combat 22 new pathogens, FDA says
Fort Worth, TX-Alcon Inc. is adding 22 susceptible pathogens to its moxifloxacin HCl 0.5% ophthalmic solution (Vigamox) in vitro labeling. The additions, which the FDA approved in late April, include atypical mycobacteria and Propionibacterium acnes. Alcon said its fourth-generation fluoroquinolone eye drop now offers the broadest spectrum in the ophthalmic fluoroquinolone category.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
